Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma

Blood (2023) 142 (Supplement 1): 4370.

https://doi.org/10.1182/blood-2023-174481

Published: 2023

Journal Articles

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Blood (2023) 142 (Supplement 1): 295.

https://doi.org/10.1182/blood-2023-173957

Published: 2023

Journal Articles

Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6411–6412.

https://doi.org/10.1182/blood-2022-169856

Published: 2022

Journal Articles

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Tove Wästerlid, Anna Warnqvist, Caroline E. Weibull, Björn E Wahlin, P-O Andersson, Gunilla Enblad, Eva Kimby, Karin Ekstroem Smedby

Blood (2022) 140 (Supplement 1): 3620–3621.

https://doi.org/10.1182/blood-2022-164550

Published: 2022

Journal Articles

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth Foon, Tina Nielsen, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers

Blood (2022) 139 (11): 1684–1693.

https://doi.org/10.1182/blood.2020010263

Published: 2022

Includes: Supplemental data

Journal Articles

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Blood (2021) 138 (Supplement 1): 3519.

https://doi.org/10.1182/blood-2021-152801

Published: 2021

Journal Articles

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Ivana Spasevska, Sarah Josefsson, PhD MSc, Yngvild Nuvin Blaker, MD PhD, Chloe B. Steen, PhD, Ankush Sharma, PhD, Kushi Kushekhar, PhD MSc, Saskia Meyer, PhD, Arne Kolstad, MD PhD, Klaus Beiske, MD PhD, Harald Holte, MD PhD, Bjørn Østenstad, MD PhD, Eva Kimby, MD PhD, Johanna Olweus, PhD, Kjetil Tasken, PhD, Suzanne Lorenz, PhD, Erlend B. Smeland, PhD MD, Ash A. Alizadeh, MD PhD, Kanutte Huse, PhD, June Helen Myklebust, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142380

Published: 2020

Journal Articles

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Caroline Weibull, Björn E Wahlin, MD PhD, Sandra Lockmer, Gunilla Enblad, Per-Ola Andersson, MD PhD, Eva Kimby, MD PhD, Karin E. Smedby, MD PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140228

Published: 2020

Journal Articles

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140933

Published: 2020

Journal Articles

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Blood (2019) 134 (Supplement_1): 2812.

https://doi.org/10.1182/blood-2019-122328

Published: 2019

Journal Articles

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Blood (2019) 134 (4): 353–362.

https://doi.org/10.1182/blood-2018-10-879643

Published: 2019

Includes: Supplemental data

Journal Articles

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise—a Nationwide Population-Based Study from Sweden

Mattias Mattsson, MD, Fredrik Sandin, Eva Kimby, MD PhD, Martin Höglund, MD PhD, Ingrid Glimelius, MD PhD

Blood (2018) 132 (Supplement 1): 3120.

https://doi.org/10.1182/blood-2018-99-114058

Published: 2018

Journal Articles

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

Sandra Lockmer, MD, Weicheng Ren, PhD, Bjorn Ostenstad, MD PhD, Marianne Brodtkorb, MD PhD, Björn E Wahlin, Qiang Pan-Hammarstrom, MD PhD, Eva Kimby, MD PhD

Blood (2018) 132 (Supplement 1): 4154.

https://doi.org/10.1182/blood-2018-99-117949

Published: 2018

Journal Articles

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

Eva Kimby, MD PhD, Sandra Lockmer, MD, Harald Holte, MD PhD, Björn E Wahlin, Hans Hagberg, MD, Peter De Nully Brown, Björn Östenstad, MD

Blood (2018) 132 (Supplement 1): 4150.

https://doi.org/10.1182/blood-2018-99-114866

Published: 2018

Journal Articles

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

Peter Dreger, Paolo Ghia, Johannes Schetelig, Michel van Gelder, Eva Kimby, Mauricette Michallet, Carol Moreno, Tadeusz Robak, Stephan Stilgenbauer, Emili Montserrat

Blood (2018) 132 (9): 892–902.

https://doi.org/10.1182/blood-2018-01-826008

Published: 2018

Includes: Supplemental data

Journal Articles

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Fie Juhl Vojdeman, MD, Lone Bredo Pedersen, Doreen Te Raa, MD PhD, Vesa Juvonen, PhD, Yvette Norden, Geir Erland Tjønnfjord, MD DMsc, Eva Kimby, Maija Itälä-Remes, MD PhD, Anton W Langerak, Ludo M. Evers, Thorsten Zenz, MD, Marinus H.J. Van Oers, MD PhD, Christian H. Geisler, MD PhD, Arnon P. Kater, MD, Carsten Utoft Niemann, MD PhD

Blood (2017) 130 (Supplement 1): 4312.

https://doi.org/10.1182/blood.V130.Suppl_1.4312.4312

Published: 2017

Journal Articles

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Carla Casulo, MD, Jennifer Le-Rademacher, PhD, Jesse Dixon, Stat, Gilles Salles, MD, Eva Hoster, Michael Herold, MD, Wolfgang Hiddemann, Catherine Sebban, MD, Robert Marcus, Eva Kimby, Howard Hochster, MD, Umberto Vitolo, MD, Emmanuel Gyan, MDPhD, Fang-Shu Ou, PhD, Tina Nielsen, Kenneth A. Foon, MD, Shi Qiuan, PhD, Christopher Flowers, MD

Blood (2017) 130 (Supplement 1): 412.

https://doi.org/10.1182/blood.V130.Suppl_1.412.412

Published: 2017

Journal Articles

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Sandra Lockmer, Bjorn Ostenstad, Hans Hagberg, Harald Holte, Björn Engelbrekt Wahlin, Chloe Beate Steen, Peter de Nully Brown, MD PhD, Eva Kimby

Blood (2017) 130 (Supplement 1): 2768.

https://doi.org/10.1182/blood.V130.Suppl_1.2768.2768

Published: 2017

Journal Articles

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Sandra Eketorp Sylvan, MD PhD, Anna Asklid, MD, Hemming Johansson, Jenny Klintman, MD PhD, Jenny Bjellvi, MD, Staffan Tolvgård, MD, Eva Kimby, Stefan Norin, MD PhD, P-O Andersson, MD PhD Prof., Claes Karlsson, MD PhD, Karin Karlsson, MD, Birgitta Lauri, MD, Mattias Mattsson, MD, Anna Bergendahl Sandstedt, MD, Maria Strandberg, MD, Anders Österborg, MD PhD Prof., Lotta Hansson

Blood (2017) 130 (Supplement 1): 1744.

https://doi.org/10.1182/blood.V130.Suppl_1.1744.1744

Published: 2017

Journal Articles

Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era

Chloe Beate Steen, Ellen Leich, June Helen Myklebust, PhD, Sandra Lockmer, Jillian Frances Wise, Björn Engelbrekt Wahlin, Bjørn Østenstad, Knut Liestol, Eva Kimby, Andreas Rosenwald, Erlend Bremertun Smeland, Harald Holte, Ole Christian Lingjærde, Marianne Brodtkorb

Blood (2017) 130 (Supplement 1): 1467.

https://doi.org/10.1182/blood.V130.Suppl_1.1467.1467

Published: 2017

NARROW

The Proliferative History Index, Epicmit, Derived from Genome-Wide Epigenomic Profiling, Is a Key Driver of Clinical Survival in Splenic Marginal Zone Lymphoma

Long-Term Efficacy of a 6-Month Regimen of Rituximab and Lenalidomide in Follicular Lymphoma Patients in Need of First Therapy: Updated Analysis of the SAKK 35/10 Randomized Trial

Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Diversity of Intratumoral Regulatory T Cells in Non-Hodgkin Lymphoma

Heterogeneity of Regulatory T Cells in B-Cell Non-Hodgkin Lymphoma

Outcome By Primary Treatment Type and Timing of Progression Among Follicular Lymphoma Patients: A Large, Population-Based Study in Sweden

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First - Line Treatment of Waldenstrom's Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Continuous Increasing Prevalence of Chronic Lymphocytic Leukemia (CLL) with an Estimated Future Rise—a Nationwide Population-Based Study from Sweden

M7-FLIPI Not Valid in Follicular Lymphoma Patients with First-Line Rituximab Chemo-Free Therapy

The PRIMA-Prognostic Index (PI) Is Valid in Follicular Lymphoma (FL) Patients with Rituximab Chemo-Free First-Line Treatment

High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies

Patients with Chronic Lymphocytic Leukemia Belonging to the B-Cell Receptor Stereotypy Subset #2 Have Long Progression Free Survival after Chemo- or Chemoimmunotherapy in the HOVON68 Trial

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Long-Term Follow-up of Patients with Indolent Lymphoma after First Line Therapy with Rituximab As Single Agent or in Combination with Interferon-α2a

Outcome of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First Line Therapy: A Swedish Nation-Wide Study on 1053 Consecutive Patients Treated between 2007 and 2013

Combined Clinical and Gene Expression Score Identifies Follicular Lymphoma Patients with High Risk of Transformation in the Rituximab Era

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only